Divi's Laboratories Moat Analysis: Score & Risks
Divi's Laboratories Ltd.
A first-pass moat teardown of Divi's Laboratories Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Intangible Assets. Provisional, single-pass evidence.
Divi's Laboratories Ltd. scores 5.35 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“most of our APIs on the generic segment are backed by long-term contracts, which have variability clauses, which protects us from such situations”
“Enhancing backward integration and manufacturing capacity, ensuring cost efficiency, supply security, and seamless regulatory compliance”
“Our Custom Synthesis segment offers contract manufacturing services of APIs and Intermediates for global innovator companies across a vast portfolio of products in diverse therapeutic areas.”
“I don't think I can foresee any, at least in the next 2 quarters, anything that is going to be in a better situation for generics than it is today”
“we being backward integrated and being a large volume supplier for several of the APIs we produce, having anywhere from 60% to 70% market share, we are able to sustain and have continuous supply and we are successful in not losing any market share”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 5.0 — below 6, so the band is capped narrow. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 113 Indian companies we have scored for moat durability — 88 narrow, 25 narrow-trending-wide, none wide. The full ranked read: Wide-Moat Stocks in India: We Scored 113 Companies and Found None. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion